Tnf

Tnf articles

4 times cancer rate in children with juvenile arthritis
New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.

Rheumatoid arthritis and psoriasis medications lowers diabetes risk
Certain rheumatoid arthritis and psoriasis medications are associated with reduced diabetes risk, revealed by researchers. 2 disease-modifying antirheumatic drugs, TNF inhibitors and hydroxychloroquine, are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients

Actemra, tocilizumab approved for Rheumatoid Arthritis
Genentech, Inc. , a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Diabetes may weaken your bones
The inflammatory molecule TNF-a may contribute to delayed bone fracture healing in diabetics, revealed by researchers. Diabetes, a condition where the body either does not produce enough, or respond to, insulin, affects at least 171 million people worldwide, a figure that is likely to double by 2030.

TNF blockers will have boxed warning cancer risk
The U.S. Food and Drug Administration is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers or TNF inhibitors.

Cimzia in prefilled syringe for Crohn's disease patients
Cimzia (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) for reducing signs and symptoms of Crohn's disease is now available for self-administration in a prefilled syringe.

UCB's Cimzia approved for rheumatoid arthritis adults
UCB announced that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

Herpes zoster or shingles risk more with rheumatoid arthritis medicines
Use of certain medications known as monoclonal anti tumor necrosis factor a (TNF-a) antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster (shingles), the painful infection characterized by blisters, according to a study in the February 18 issue of JAMA.

8 Tnf articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
17.61